Barclays PLC Has $1.01 Million Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Barclays PLC raised its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 143.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 595,150 shares of the biotechnology company’s stock after buying an additional 350,196 shares during the period. Barclays PLC’s holdings in Pacific Biosciences of California were worth $1,011,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC raised its stake in Pacific Biosciences of California by 641.3% in the third quarter. FMR LLC now owns 408,151 shares of the biotechnology company’s stock valued at $694,000 after buying an additional 353,092 shares during the period. Squarepoint Ops LLC bought a new stake in Pacific Biosciences of California in the second quarter valued at approximately $719,000. State Street Corp raised its stake in Pacific Biosciences of California by 5.7% in the third quarter. State Street Corp now owns 6,276,156 shares of the biotechnology company’s stock valued at $10,669,000 after buying an additional 340,766 shares during the period. Soros Fund Management LLC raised its stake in Pacific Biosciences of California by 23.6% in the third quarter. Soros Fund Management LLC now owns 2,098,000 shares of the biotechnology company’s stock valued at $3,567,000 after buying an additional 400,000 shares during the period. Finally, Senvest Management LLC raised its stake in Pacific Biosciences of California by 36.1% in the third quarter. Senvest Management LLC now owns 1,093,954 shares of the biotechnology company’s stock valued at $1,860,000 after buying an additional 290,000 shares during the period.

Pacific Biosciences of California Price Performance

Pacific Biosciences of California stock opened at $1.79 on Tuesday. The stock’s fifty day moving average price is $2.00 and its two-hundred day moving average price is $1.77. Pacific Biosciences of California, Inc. has a one year low of $1.16 and a one year high of $9.99. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64. The firm has a market cap of $490.22 million, a PE ratio of -1.23 and a beta of 1.95.

Analyst Ratings Changes

Several analysts have issued reports on the company. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price objective on the stock. in a research note on Monday, November 11th. Scotiabank lowered their target price on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research note on Monday, November 11th. StockNews.com upgraded Pacific Biosciences of California to a “sell” rating in a research note on Tuesday, November 12th. Finally, Piper Sandler increased their target price on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pacific Biosciences of California currently has an average rating of “Hold” and a consensus price target of $2.95.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.